You are here: Industry Insights > Perjeta

News List

Financial Report: Roche 1H Results contractpharma
July 23, 2021
Diagnostics Division sales grew 49% due to high demand for COVID-19 tests and strong momentum in routine testing.
UK cancer centre to offer breast cancer treatment at home pharmatimes
April 29, 2021
The Christie NHS Foundation Trust has become the first cancer centre in the UK to offer the treatment Phesgo, developed by Roche’s Genentech division, for breast cancer at home.
Halozyme Announces FDA Accepted BLA for Fixed-Dose Subcutaneous Perjeta, Herceptin Combination americanpharmaceuticalreview
March 05, 2020
Halozyme Therapeutics announced the U.S. Food and Drug Administration has accepted a Biologics License Application (BLA) from Genentech ...
Data shows non-inferiority of SC administration of Roche’s Perjeta and Herceptin pharmaceutical-technology
December 16, 2019
Roche has published data demonstrating non-inferiority of a fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) administered through ...
Price cut unlocks NICE nod for Perjeta in post-surgery breast cancer pharmaphorum
February 15, 2019
Roche has finally won NICE backing for the use of Perjeta (pertuzumab) to prevent early-stage HER2-positive breast cancer from recurring after surgery, at the third attempt.
SMC accepts four medicines for NHS use pharmatimes
December 11, 2018
Roche’s Perjeta, a medicine used to treat early stage breast cancer, has been accepted by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland.